Nasdaq · CIK 0001447028
ABUS Arbutus Biopharma Corp
Insider trading from SEC Form 4. Last filing 5 d ago. Close $4.22 on Oct 9, 2026, +15% from the 52-week low and -19% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Price and insider trades, last year
ABUSOct 9, 2026 · close 4.22
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Arbutus Biopharma Corp, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | J. Christopher Naftzger General Counsel and CCO sell | $37k 11,333 shares | -12% | - | |
| 29Weak | Michael J. McElhaugh Interim President & CEO sell | $78k 23,790 shares | -2% | - | |
| 23Weak | Karen Sims Chief Medical Officer sell | $64k 19,348 shares | -15% | - | |
| 30Weak | David C Hastings Chief Financial Officer sell | $73k 22,183 shares | -12% | - |
Transactions
The last 47 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Roger Sawhney director | DDisposition to issuer Common Shares | -17,142 | $5.00 | $86k | 13,683 | 5 d ago |
| Oct 1, 2026 | Tuan Nguyen Chief Financial Officer | DDisposition to issuer Common Shares | -48,081 | $5.00 | $240k | 111,882 | 5 d ago |
| Oct 1, 2026 | Robert A Beardsley director | DDisposition to issuer Common Shares | -17,948 | $5.00 | $90k | 14,328 | 5 d ago |
| Oct 1, 2026 | Lindsay Androski President and CEO | DDisposition to issuer Common Shares | -24,655 | $5.00 | $123k | 47,682 | 5 d ago |
| Oct 1, 2026 | Roivant Sciences Ltd. director, owner | DDisposition to issuer Common Shares | -8,967,383 | $5.00 | $45M | 29,880,079 | 7 d ago |
| Sep 18, 2026 | Lindsay Androski President and CEO | MOption exercise Common Shares | +116,408 | $3.20 | $373k | 144,408 | 19 d ago |
| Sep 18, 2026 | Roger Sawhney director | MOption exercise Common Shares | +52,533 | $3.34 | $175k | 52,533 | 19 d ago |
| Sep 18, 2026 | Robert A Beardsley director | MOption exercise Common Shares | +52,533 | $3.20 | $168k | 52,533 | 19 d ago |
| Sep 18, 2026 | Tuan Nguyen Chief Financial Officer | MOption exercise Common Shares | +265,625 | $3.49 | $927k | 339,125 | 19 d ago |
| Sep 18, 2026 | Lindsay Androski President and CEO | MOption exercise Common Shares | +10,456 | $4.39 | $46k | 154,864 | 19 d ago |
| Sep 18, 2026 | Roger Sawhney director | MOption exercise Common Shares | +78,800 | $4.24 | $334k | 131,333 | 19 d ago |
| Sep 18, 2026 | Robert A Beardsley director | MOption exercise Common Shares | +78,800 | $4.24 | $334k | 131,333 | 19 d ago |
| Sep 18, 2026 | Tuan Nguyen Chief Financial Officer | MOption exercise Common Shares | +27,475 | $4.39 | $121k | 366,600 | 19 d ago |
| Sep 18, 2026 | Roger Sawhney director | FTax withholding Common Shares | -100,508 | $5.07 | $510k | 30,825 | 19 d ago |
| Sep 18, 2026 | Robert A Beardsley director | FTax withholding Common Shares | -99,057 | $5.07 | $502k | 32,276 | 19 d ago |
| Sep 18, 2026 | Tuan Nguyen Chief Financial Officer | FTax withholding Common Shares | -206,637 | $5.07 | $1.0M | 159,963 | 19 d ago |
| Sep 18, 2026 | Lindsay Androski President and CEO | FTax withholding Common Shares | -82,527 | $5.07 | $418k | 72,337 | 19 d ago |
| Sep 18, 2026 | Tuan Nguyen Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative | -265,625 | $0.00 | $0 | 484,375 | 19 d ago |
| Sep 18, 2026 | Robert A Beardsley director | MOption exercise Stock Option (Right to Buy)derivative | -52,533 | $0.00 | $0 | 105,067 | 19 d ago |
| Sep 18, 2026 | Lindsay Androski President and CEO | MOption exercise Stock Option (Right to Buy)derivative | -116,408 | $0.00 | $0 | 194,014 | 19 d ago |
| Sep 18, 2026 | Roger Sawhney director | MOption exercise Stock Option (Right to Buy)derivative | -52,533 | $0.00 | $0 | 105,067 | 19 d ago |
| Sep 18, 2026 | Roger Sawhney director | MOption exercise Stock Option (Right to Buy)derivative | -78,800 | $0.00 | $0 | 0 | 19 d ago |
| Sep 18, 2026 | Robert A Beardsley director | MOption exercise Stock Option (Right to Buy)derivative | -78,800 | $0.00 | $0 | 0 | 19 d ago |
| Sep 18, 2026 | Lindsay Androski President and CEO | MOption exercise Stock Option (Right to Buy)derivative | -10,456 | $0.00 | $0 | 61,244 | 19 d ago |
| Sep 18, 2026 | Tuan Nguyen Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative | -27,475 | $0.00 | $0 | 160,925 | 19 d ago |
| Feb 2, 2026 | Lindsay Androski President and CEO | AGrant or award Common Shares | +28,000 | $0.00 | $0 | 28,000 | Feb 2, 2026 |
| Feb 2, 2026 | Tuan Nguyen Chief Financial Officer | AGrant or award Common Shares | +73,500 | $0.00 | $0 | 73,500 | Feb 2, 2026 |
| Feb 2, 2026 | Lindsay Androski President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +71,700 | $0.00 | $0 | 71,700 | Feb 2, 2026 |
| Feb 2, 2026 | Tuan Nguyen Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +188,400 | $0.00 | $0 | 188,400 | Feb 2, 2026 |
| Aug 4, 2025 | Roger Sawhney director | AGrant or award Stock Option (Right to Buy)derivative | +157,600 | $0.00 | $0 | 157,600 | Aug 6, 2025 |
| Mar 31, 2025 | Tuan Nguyen Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +750,000 | $0.00 | $0 | 750,000 | Apr 1, 2025 |
| Mar 31, 2025 | Tuan Nguyen Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +750,000 | $0.00 | $0 | 750,000 | Mar 31, 2025 |
| Mar 18, 2025 | Lindsay Androski President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +310,422 | $0.00 | $0 | 310,422 | Mar 20, 2025 |
| Mar 18, 2025 | Anuj Hasija director | AGrant or award Stock Option (Right to Buy)derivative | +157,600 | $0.00 | $0 | 157,600 | Mar 20, 2025 |
| Mar 18, 2025 | Robert A Beardsley director | AGrant or award Stock Option (Right to Buy)derivative | +157,600 | $0.00 | $0 | 157,600 | Mar 20, 2025 |
| Feb 14, 2025 | Karen Sims Chief Medical Officer | AGrant or award Common Shares | +49,300 | $0.00 | $0 | 155,494 | Feb 19, 2025 |
| Feb 14, 2025 | David C Hastings Chief Financial Officer | AGrant or award Common Shares | +90,100 | $0.00 | $0 | 249,824 | Feb 19, 2025 |
| Feb 14, 2025 | Michael J. McElhaugh Interim President & CEO | AGrant or award Common Shares | +177,000 | $0.00 | $0 | 1,658,003 | Feb 19, 2025 |
| Feb 14, 2025 | J. Christopher Naftzger General Counsel and CCO | AGrant or award Common Shares | +54,300 | $0.00 | $0 | 140,544 | Feb 19, 2025 |
| Feb 14, 2025 | Karen Sims Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +200,300 | $0.00 | $0 | 200,300 | Feb 19, 2025 |
| Feb 14, 2025 | David C Hastings Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +365,800 | $0.00 | $0 | 365,800 | Feb 19, 2025 |
| Feb 14, 2025 | Michael J. McElhaugh Interim President & CEO | AGrant or award Stock Option (Right to Buy)derivative | +718,800 | $0.00 | $0 | 718,800 | Feb 19, 2025 |
| Feb 14, 2025 | J. Christopher Naftzger General Counsel and CCO | AGrant or award Stock Option (Right to Buy)derivative | +220,300 | $0.00 | $0 | 220,300 | Feb 19, 2025 |
| Feb 4, 2025 | J. Christopher Naftzger General Counsel and CCO | SOpen-market sale Common Shares10b5-1 | -11,333 | $3.28 | $37k | 86,244 | Feb 5, 2025 |
| Feb 4, 2025 | Michael J. McElhaugh Interim President & CEO | SOpen-market sale Common Shares10b5-1 | -23,790 | $3.28 | $78k | 1,481,003 | Feb 5, 2025 |
| Feb 4, 2025 | Karen Sims Chief Medical Officer | SOpen-market sale Common Shares10b5-1 | -19,348 | $3.28 | $64k | 106,194 | Feb 5, 2025 |
| Feb 4, 2025 | David C Hastings Chief Financial Officer | SOpen-market sale Common Shares10b5-1 | -22,183 | $3.28 | $73k | 159,724 | Feb 5, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Lindsay AndroskiPresident and CEO
- Robert A Beardsleydirector
- David C HastingsChief Financial Officer
- Anuj Hasijadirector
- Michael J. McElhaughInterim President & CEO
- J. Christopher NaftzgerGeneral Counsel and CCO
- Tuan NguyenChief Financial Officer
- Roivant Sciences Ltd.director, owner
- Roger Sawhneydirector
- Karen SimsChief Medical Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.